BioNTech Investor Day Presentation Deck

Fix Vac | BNT111 - Tumor shrinkage observed in patients receiving BNT111 monotherapy or combination with a PD-1 inhibitor 1,2 Best change from baseline in target lesion Best change from baseline in target lesion (%) 100 80 60 40 20 0 -20 -40 -60 -80 -100 CPI નજી MONOTHERAPY MONOTHERAPY MONOTHERAPY CPI Adv dar MONOTHERAPY MONOTHERAPY MONOTHERAPY MONOTHERAPY MONOTHERAPY CPI dy CPL CPT MONOTHERAPY MONOTHERAPY RAPY CPI CPI MONOTHERAPY MONOTHERAPY CPI de MONOTHERAPY MONOTHERAPY in CPI O CPI NALE CPI MONOTHERAPY CPI The O MONOTHERAPY MONOTHERAPY O O CPI CPI o CPI S CPI ADV O Adv MONOTHERAPY MONOTHERAPY CPI 199 MONOTHERAPY ** CPL CPT * * * * CPL CFI CPI on BRAF/MEK MONOTHERAPY MONOTHERAPY CPI * MONOTHERAPY * * de CPT CPL * CPI OFI CPI CPI Maximal dose given [µg] 14,4 29 50 75 100 Best overall response * PR o SD/irSD Data cut-off: May 24, 2021. 1 One patient had an 83.2% decrease of target lesion from baseline but experienced a new target lesion and had SD as the best overall response. Patient B4-31 had several new lesions despite a reduction in the target lesions; 2 One patient in the BNT111 monotherapy group who achieved a CR is not shown as only non-measurable target lesions were present (which later disappeared). CPI, checkpoint inhibitor; irRECIST, immune-related response evaluation criteria in solid tumors; SD, stable disease. LUTIN mRNA cancer vaccines BIONTECH 111

View entire presentation